real peptides FAQ

Use separate cohorts with route-matched controls rather than forcing both peptides into the same route. If Peptide A performs better via IM and AHK-Cu performs better via SubQ, administering both via the same route introduces a systematic bias that compromises internal validity. Document route selection for each compound based on published pharmacokinetic data and include route as a controlled variable in your analysis.

No. The application frequency remains twice daily at 12-hour intervals regardless of concentration within the 0.5–2.0% range. Lower concentrations deliver proportionally less peptide per application, but increasing frequency doesn't compensate effectively because the issue isn't total peptide dose. It's sustained receptor occupancy. A 1% solution applied twice daily maintains therapeutic follicular copper levels; applying it three or four times daily at the same concentration increases cumulative copper load without proportionally increasing efficacy, and raises the risk of pro-oxidant effects from excess free copper dissociation.

Possibly, but unproven. Injectable administration bypasses first-pass hepatic metabolism, potentially increasing bioavailability. But the liver is the target organ for lipotropic activity, so bypassing it may not confer the advantage it does with other compounds. No comparative bioavailability studies exist for LIPO-C formulations. The injectable doses used clinically (25–50mg per component) are lower than the oral doses tested in human trials (400–4,000mg), which showed metabolic effects without fat loss. If the mechanism doesn't produce fat loss at higher oral doses, lower injectable doses are unlikely to change the outcome.

Absence of inflammatory marker reduction by week 8 indicates insufficient senolytic activity. Either the dose was too low, the subject's senescent cell burden was lower than expected, or the peptide quality was compromised. Review dosing (institutional protocols typically use 5–10 mg FOXO4-DRI per administration), confirm proper reconstitution and storage (lyophilized peptide stored at -20°C, reconstituted solution refrigerated at 2–8°C and used within 28 days), and consider repeat cycle at higher dose or combination with quercetin + fisetin to enhance senolytic clearance.

Hold your current dose for two weeks and retest. Transient ALT elevation (40–60 U/L) during lipotropic therapy often reflects accelerated hepatic fat mobilisation, not liver damage, and typically normalises within 10–14 days as the liver adapts to increased VLDL secretion. If ALT exceeds 80 U/L or AST exceeds 60 U/L, discontinue LIPO-C and assess for underlying hepatic pathology (NAFLD, medication interactions, alcohol use). Resume at 50% of the previous dose only after enzymes return to baseline (ALT under 40 U/L, AST under 35 U/L).

Ipamorelin is not FDA-approved for hair loss treatment and should not be used outside supervised research protocols. If you're experiencing androgenetic alopecia, telogen effluvium, or other hair thinning conditions, evidence-based first-line therapies include topical minoxidil (FDA-approved for male and female pattern hair loss) and oral finasteride or dutasteride (5α-reductase inhibitors with established efficacy in reducing scalp DHT). Ipamorelin's investigational status means safety, dosing, and long-term outcomes in this indication remain undefined.

Verify the cell model first. FOXO4-DRI selectively induces apoptosis in senescent cells, not proliferating cells. If the culture wasn't properly senescence-induced (via ionizing radiation, replicative exhaustion, or oncogene activation), FOXO4-DRI won't produce measurable effects. Confirm senescence markers: elevated SA-β-gal activity, p16 and p21 expression, and SASP cytokine secretion. If markers are present and preparation was correct, the issue may be incubation time. FOXO4-DRI-induced apoptosis peaks 24–72 hours post-administration depending on cell type. Some fibroblast lines require 48-hour incubations to show significant clearance.

Discard the vial immediately. Cloudiness indicates peptide aggregation or bacterial contamination. Either renders the solution unusable. Aggregated peptides can't bind MC1R receptors effectively, and contaminated solutions introduce confounding variables into your research model. Reconstitute a fresh vial using bacteriostatic water at refrigerated temperature, ensuring sterile technique throughout. Cloudiness within 72 hours suggests either improper reconstitution technique or compromised bacteriostatic water.

Reduce dose by 50% and retest AST/ALT in two weeks. Transient elevations between 45–55 U/L often resolve with dose reduction, while continued climbing above 60 U/L requires protocol suspension. NNMT is highly expressed in hepatic tissue. Enzyme inhibition in the liver creates local metabolic shifts that some individuals tolerate better than others. Genetic polymorphisms in methylation enzymes (MTHFR, COMT) may predict hepatic response, though this remains under investigation. If enzymes stabilise at reduced dose, continue at that level; if they continue rising, discontinue and reassess after full normalisation.

Discard it immediately. Cloudiness or discoloration (especially a shift from clear/pale blue to brown or yellow) indicates peptide oxidation and copper complex degradation. Oxidized copper peptides not only lose therapeutic activity. They can generate reactive oxygen species that damage follicular tissue. Properly formulated AHK-Cu in a buffered carrier stored at 2–8°C should remain clear to pale blue for 28–30 days. Visible color change, precipitate formation, or turbidity are failure markers. The peptide structure has degraded, and applying it delivers inactive fragments or pro-oxidant copper ions rather than functional peptide.

Use the batch if the research protocol allows for ±2% purity variation. Many applications tolerate this range without affecting outcomes. The more critical question is what comprises the remaining 4%: deletion sequences and incomplete peptides are preferable to solvent residues or unidentified contaminants. Third-party COAs should specify impurity composition. If they don't, request detailed HPLC chromatograms. Real Peptides maintains ≥98% purity because tighter tolerances reduce experimental variability, but 96% from a verified third-party source is more trustworthy than an unverified 99% claim.

The peptide remains stable in solution at room temperature for 4–6 hours, but senolytic potency begins declining after that window. D-retro-inverso peptides are more stable than their L-amino acid counterparts, but extended ambient exposure still promotes slow hydrolysis of peptide bonds. If the solution was out for fewer than 6 hours, refrigerate immediately at 2–8°C and use within 48 hours. If exposure exceeded 6 hours or the solution was left overnight, activity loss may reach 20–40%. Consider this a compromised batch and adjust dosing upward by 25–30% or prepare fresh solution.

No published human trial has tested this directly. The theoretical mechanism. Improved hepatic VLDL assembly and fat export. Could support liver health during weight loss, but that's distinct from accelerating adipose tissue lipolysis. If you're losing fat through caloric restriction, LIPO-C might prevent fatty liver accumulation, but it won't meaningfully increase the rate of fat loss beyond what the deficit already produces. The rodent studies that showed hepatic improvements didn't report faster weight loss in supplemented groups.

Mild transient flushing within 30–60 minutes of KPV administration reflects melanocortin receptor activation in dermal blood vessels. It's a pharmacological effect, not an allergic reaction. The sensation typically resolves within 1–2 hours and diminishes with repeated dosing as receptor sensitivity normalizes. If flushing is accompanied by hives, difficulty breathing, or throat tightness, discontinue immediately and consult a healthcare provider. True hypersensitivity to peptides is rare but requires medical evaluation.

No. Do not double-dose to compensate for a missed application. Snap-8 efficacy is limited by SNARE binding site availability, not peptide quantity. Applying 20% concentration in a single dose does not produce twice the effect of 10%. It saturates receptors at the same rate and the excess peptide is degraded without contributing to muscle relaxation. Resume your regular twice-daily schedule at standard concentration. Missing one evening dose reduces cumulative efficacy by approximately 8–10% over a week, which is recoverable within 3–4 days of consistent dosing.

Injection site reactions (erythema, induration, mild pain) occur in 8–12% of AHK-Cu administrations regardless of route, typically resolving within 48–72 hours. These are local inflammatory responses to copper ions rather than route-specific complications. SubQ injections show slightly lower reaction rates (8% vs 12% IM) because adipose tissue has lower immune cell density. Rotate injection sites, use smaller volumes per site (≤0.5 mL), and verify peptide pH is between 6.5–7.5 before administration. Acidic solutions increase reaction probability.

Extend the current dose interval by an additional 2–4 weeks rather than escalating on schedule. Persistent nausea beyond the typical 4–6 week adaptation window signals that gastric GLP-1 receptor downregulation hasn't kept pace with dose. Pushing to the next level compounds the problem. Eating smaller meals (250–350 calories every 3–4 hours instead of three large meals), avoiding high-fat foods that further delay gastric emptying, and not lying down within two hours of eating are mechanism-based interventions, not vague lifestyle tips. If nausea remains severe after extending the dose interval, consider stepping back to the previous dose for four weeks before re-attempting escalation. The goal is sustained therapy, not rapid titration.

Every Real Peptides vial ships with a lot number printed on the label. Visit the Real Peptides website and enter that lot number in the batch verification portal to access the full third-party HPLC chromatogram, mass spectrometry results, and endotoxin testing data for your specific production batch. This documentation meets institutional research standards requiring independently verified compound purity and identity confirmation.

No, but potency is reduced. If reconstituted within the last 24 hours, you can salvage partial efficacy by continuing to use the vial at slightly higher doses to compensate (1.2–1.5mg instead of 1mg per injection). The aggregation caused by cold-water reconstitution isn't complete denaturation. It's partial clumping that reduces solubility and bioavailability. Future vials must use room-temperature solvent. If the vial is older than 48 hours and shows no visible results, discard it and start fresh with corrected technique.

Check the thermal indicator strip inside the package immediately upon delivery. If the strip shows temperature breach (typically red or activated zone), contact Real Peptides for immediate replacement. Do not reconstitute or use the compound. Temperature excursions above 8°C for more than 6 hours cause partial denaturation of peptides like Cerebrolysin, reducing potency by 15–30% even if visual appearance remains unchanged. No at-home test can confirm potency loss, so thermal monitoring is the only reliable verification method.